The GlaxoSmithKline and Celgene-backed immunotherapy developer has revealed its intention to float on the Nasdaq Global Market.
Lyell Immunopharma, a US-based immunotherapy developer backed by pharmaceutical firms GlaxoSmithKline (GSK) and Celgene, filed for a $150m initial public offering on the Nasdaq Global Market on Tuesday.
Founded in 2018, Lyell is developing immunotherapies for cancer patients that are intended to prevent T cells, a critical component of the immune system, from becoming dysfunctional. Its lead drug candidate, LYL797, is being developed to treat non-small cell lung cancer and triple-negative breast cancer.
In October 2019, the company sealed…
